| Nebulized magnesium sulfate in the management of acute exacerbations of asthma. | |
| | |
MedLine Citation:
|
PMID: 16735656 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To evaluate the efficacy and safety of nebulized magnesium sulfate in the treatment of acute exacerbations of asthma. DATA SOURCES: MEDLINE, EMBASE, and PubMed (all to October 2005) were searched using the key words magnesium, magnesium sulfate, magnesium compounds, nebulise, nebulize, vaporise, vaporize, nebulizers and vaporizers, aerosols, asthma, exacerbation, bronchial spasm, and bronchospasm. STUDY SELECTION AND DATA EXTRACTION: Prospective, randomized, controlled trials that evaluated efficacy and safety endpoints of nebulized magnesium sulfate in the management of acute exacerbations of asthma were included. All studies were evaluated independently by both authors. Efficacy outcomes included pulmonary function, clinical disease severity (as defined by each study), and rate of hospitalization. Safety outcomes were as described by each trial. DATA SYNTHESIS: Six prospective trials met the study criteria. Nebulized magnesium alone failed to demonstrate any benefit compared with beta(2)-agonists alone at improving pulmonary function. In trials in which nebulized magnesium was used as a vehicle for albuterol, there appear to be additional benefits to albuterol therapy in terms of improvements in pulmonary function in a population with mild-to-moderate asthma. The heterogeneous patient populations, study designs, magnesium doses, and the delivery methods preclude the extrapolation of these results to current clinical practice. CONCLUSIONS: The studies included in this review fail to clarify the role of nebulized magnesium sulfate; therefore, this therapy cannot be recommended at this time. Future studies evaluating the role of nebulized magnesium as an adjunct therapy to beta(2)-agonist, anticholinergic, and corticosteroid therapy are necessary to determine whether a clinically relevant benefit of this intervention exists. |
| | |
Authors:
|
Eric J Villeneuve; Peter J Zed |
Related Documents
:
|
356916 - Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo. 18294736 - 18-month study of intravenous immunoglobulin for treatment of mild alzheimer disease. 19642026 - Selective immune adsorption treatment of severe guillain barré syndrome in the intensi... 14964576 - Nephrotic syndrome caused by membranous nephropathy: response to a short course of cycl... 21779816 - Is there an additional benefit of serial nt-probnp measurements in patients with stable... 20643396 - Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothe... |
Publication Detail:
|
Type: Journal Article; Review Date: 2006-05-30 |
Journal Detail:
|
Title: The Annals of pharmacotherapy Volume: 40 ISSN: 1060-0280 ISO Abbreviation: Ann Pharmacother Publication Date: 2006 Jun |
Date Detail:
|
Created Date: 2006-06-07 Completed Date: 2006-08-23 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9203131 Medline TA: Ann Pharmacother Country: United States |
Other Details:
|
Languages: eng Pagination: 1118-24 Citation Subset: IM |
Affiliation:
|
Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acute Disease Administration, Inhalation Aerosols Animals Anti-Asthmatic Agents / administration & dosage*, therapeutic use* Asthma / complications*, drug therapy* Clinical Trials as Topic Humans Magnesium Sulfate / administration & dosage*, therapeutic use* Nebulizers and Vaporizers |
| Chemical | |
Reg. No./Substance:
|
0/Aerosols; 0/Anti-Asthmatic Agents; 7487-88-9/Magnesium Sulfate |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.
Next Document: Effect of Graves' disease and methimazole on warfarin anticoagulation.